Abstract
Breast cancer is a frequent malignancy seen in population and accurate staging at diagnosis and early diagnosis of recurrence in the follow-up have a critical importance in order to offer accurate therapy options and improvement of survival. At every step of the course of the disease, anatomic and functional imaging modalities are used together to obtain the most accurate results. Hybrid positron emission tomography/magnetic resonance imaging (PET/MRI) systems provide more reliable information in oncology patients combining metabolic information obtained from PET, which has gained worldwide availability recently, and MRI, which is the best method in soft tissue imaging, by putting the advantages of the both methods together. In this review, the contributions of PET/MRI in breast cancer and its probable disadvantages will be discussed in comparison with conventional imaging methods.
Keywords: Breast cancer, positron emission tomography, magnetic resonance imaging.
References
Sung H, Ferlay J, Siegel RL, et al. Global Cancer Statistics 2020: GLOBOCAN estimates of ıncidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71:209-249.
Roginski M, Sifaki-Pistolla D, Stomby A, et al. Paradoxes of breast cancer incidence and mortality in two corners of Europe. BMC Cancer. 2022;22:1123.
Groheux D, Espié M, Giacchetti S, Hindié E. Performance of FDG PET/CT in the clinical management of breast cancer. Radiology. 2013;266:388-405.
Pujara AC, Kim E, Axelrod D, Melsaether AN. PET/MRI in breast cancer. J Magn Reson Imaging. 2019;49:328-342.
Bos R, van Der Hoeven JJ, van Der Wall E, et al. Biologic correlates of (18)fluorodeoxyglucose uptake in human breast cancer measured by positron emission tomography. J Clin Oncol. 2002;20:379-87.
Groheux D, Giacchetti S, Moretti JL, et al. Correlation of high 18F-FDG uptake to clinical, pathological and biological prognostic factors in breast cancer. Eur J Nucl Med Mol Imaging. 2011;38:426-435.
Ueda S, Tsuda H, Asakawa H, et al. Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer. Jpn J Clin Oncol. 2008;38:250-258.
Kim BS, Sung SH. Usefulness of 18F-FDG uptake with clinicopathologic and immunohistochemical prognostic factors in breast cancer. Ann Nucl Med. 2012;26:175-183.
Basu S, Chen W, Tchou J, et al. Comparison of triple-negative and estrogen receptor-positive/progesterone receptor-positive/HER2-negative breast carcinoma using quantitative fluorine-18 fluorodeoxyglucose/positron emission tomography imaging parameters: a potentially useful method for disease characterization. Cancer. 2008;112:995-1000.
Buck A, Schirrmeister H, Kühn T, et al. FDG uptake in breast cancer: correlation with biological and clinical prognostic parameters. Eur J Nucl Med Mol Imaging. 2002;29:1317-1323.
van Kruchten M, de Vries EGE, Brown M, et al. PET imaging of oestrogen receptors in patients with breast cancer. Lancet Oncol. 2013;14:e465-e475.
Gemignani ML, Patil S, Seshan VE, et al. Feasibility and predictability of perioperative PET and estrogen receptor ligand in patients with invasive breast cancer. J Nucl Med. 2013;54:1697-1702.
Evangelista L, Filippi L, Schillaci O. What radiolabeled FAPI pet can add in breast cancer? A systematic review from literature. Ann Nucl Med. 2023;37:442-450.
Helczynska K, Kronblad A, Jögi A, et al. Hypoxia promotes a dedifferentiated phenotype in ductal breast carcinoma in situ. Cancer Res. 2003;63:1441-1444.
Cooper C, Liu GY, Niu YL, Santos S, Murphy LC, Watson PH. Intermittent hypoxia induces proteasome-dependent down-regulation of estrogen receptor alpha in human breast carcinoma. Clin Cancer Res. 2004;10:8720-8727.
Carmona-Bozo JC, Manavaki R, Miller JL, et al. PET/MRI of hypoxia and vascular function in ER-positive breast cancer: correlations with immunohistochemistry. Eur Radiol. 2023;33:6168-6178.
Asano A, Ueda S, Kuji I, et al. Intracellular hypoxia measured by 18F-fluoromisonidazole positron emission tomography has prognostic impact in patients with estrogen receptor-positive breast cancer. Breast Cancer Res. 2018;20:78.
Andrzejewski P, Wengert G, Helbich TH, et al. Sequential [18F]FDG-[18F]FMISO PET and multiparametric MRI at 3T for ınsights into breast cancer heterogeneity and correlation with patient outcomes: first clinical experience. Contrast Media Mol Imaging. 2019;2019:1307247.
Mileva M, de Vries EGE, Guiot T, et al. Molecular imaging predicts lack of T-DM1 response in advanced HER2-positive breast cancer (final results of ZEPHIR trial). NPJ Breast Cancer. 2024;10:4.
Romeo V, Helbich TH, Pinker K. Breast PET/MRI hybrid imaging and targeted tracers. J Magn Reson Imaging. 2023;57:370-386.
Dorrius MD, Dijkstra H, Oudkerk M, Sijens PE. Effect of b value and pre-admission of contrast on diagnostic accuracy of 1.5-T breast DWI: a systematic review and meta-analysis. Eur Radiol. 2014;24:2835-2347.
Nguyen VT, Rahbar H, Olson ML, Liu CL, Lehman CD, Partridge SC. Diffusion-weighted imaging: Effects of intravascular contrast agents on apparent diffusion coefficient measures of breast malignancies at 3 Tesla. J Magn Reson Imaging. 2015;42:788-800.
Jannusch K, Lindemann ME, Bruckmann NM, et al. Towards a fast PET/MRI protocol for breast cancer imaging: maintaining diagnostic confidence while reducing PET and MRI acquisition times. Eur Radiol. 2023;33:6179-6188.
Chung HW, Park KS, Lim I, et al. PET/MRI and novel targets for breast cancer. Biomedicines. 2024;12:172.
Panico C, Ferrara F, Woitek R, et al. Staging breast cancer with MRI, the T. a key role in the neoadjuvant setting. Cancers (Basel). 2022;14:5786.
Mann RM, Cho N, Moy L. Breast MRI: state of the art. Radiology. 2019;292:520-536.
Grueneisen J, Nagarajah J, Buchbender C, et al. Positron emission tomography/magnetic resonance ımaging for local tumor staging in patients with primary breast cancer: a comparison with positron emission tomography/computed tomography and magnetic resonance ımaging. Invest Radiol. 2015;50:505-513.
Goorts B, Vöö S, van Nijnatten TJA, et al. Hybrid 18F-FDG PET/MRI might improve locoregional staging of breast cancer patients prior to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2017;44:1796-1805.
Moon EH, Lim ST, Han YH, et al. usefulness of F-18 FDG PET/CT-mammography for preoperative staging of breast cancer: comparison with conventional PET/CT and MR-mammography. Radiol Oncol. 2013;47:390-397.
Robertson IJ, Hand F, Kell MR. FDG-PET/CT in the staging of local/regional metastases in breast cancer. Breast. 2011;20:491-494.
Veronesi U, De Cicco C, Galimberti VE, et al. A comparative study on the value of FDG-PET and sentinel node biopsy to identify occult axillary metastases. Ann Oncol. 2007;18:473-478.
Morawitz J, Bruckmann NM, Dietzel F, et al. Comparison of nodal staging between CT, MRI, and [18F]-FDG PET/MRI in patients with newly diagnosed breast cancer. Eur J Nucl Med Mol Imaging. 2022;49:992-1001.
Morawitz J, Bruckmann NM, Jannusch K, et al. Conventional imaging, MRI and 18F-FDG PET/MRI for N and M staging in patients with newly diagnosed breast cancer. Cancers (Basel). 2023;15:3646.
de Mooij CM, Sunen I, Mitea C, et al. Diagnostic performance of PET/computed tomography versus PET/MRI and diffusion-weighted imaging in the N- and M-staging of breast cancer patients. Nucl Med Commun. 2020;41:995-1004.
Zhang C, Liang Z, Liu W, Zeng X, Mo Y. Comparison of whole-body 18F-FDG PET/CT and PET/MRI for distant metastases in patients with malignant tumors: a meta-analysis. BMC Cancer. 2023;23:37.
Backhaus P, Burg MC, Roll W, et al. Simultaneous FAPI PET/MRI targeting the fibroblast-activation protein for breast cancer. Radiology. 2022;302:39-47.
Carmona-Bozo JC, Manavaki R, Woitek R, et al. Hypoxia and perfusion in breast cancer: simultaneous assessment using PET/MR imaging. Eur Radiol. 2021;31:333-344.
Gradishar WJ, Moran MS, Abraham J, et al. Breast Cancer, Version 3.2022, NCCN clinical practice guidelines in oncology. J Natl Compr Canc Netw. 2022;20:691-722.
Sawicki LM, Grueneisen J, Schaarschmidt BM, et al. Evaluation ofF-FDG PET/MRI, F-FDG PET/CT, MRI, and CT in whole-body staging of recurrent breast cancer. Eur J Radiol. 2016;85:459-465.
Lin CY, Lin CL, Kao CH. Staging/restaging performance of F18-fluorodeoxyglucose positron emission tomography/magnetic resonance imaging in breast cancer: A review and meta-analysis. Eur J Radiol. 2018;107:158-165.
Jena A, Taneja S, Singh A, et al. Association of pharmacokinetic and metabolic parameters derived using simultaneous PET/MRI: Initial findings and impact on response evaluation in breast cancer. Eur J Radiol. 2017;92:30-36.
Wang J, Shih TT, Yen RF. Multiparametric evaluation of treatment response to neoadjuvant chemotherapy in breast cancer using ıntegrated PET/MR. Clin Nucl Med. 2017;42:506-513.
Cho N, Im SA, Cheon GJ, et al. Integrated 18F-FDG PET/MRI in breast cancer: early prediction of response to neoadjuvant chemotherapy. Eur J Nucl Med Mol Imaging. 2018;45:328-339.
Sekine C, Uchiyama N, Watase C, et al. Preliminary experiences of PET/MRI in predicting complete response in patients with breast cancer treated with neoadjuvant chemotherapy. Mol Clin Oncol. 2022;16:50.
de Mooij CM, van Nijnatten TJA, Goorts B, et al. Prediction of primary tumour and axillary lymph node response to neoadjuvant chemo(targeted) therapy with dedicated breast [18F]FDG PET/MRI in breast cancer. Cancers (Basel). 2023;15:401.
Umutlu L, Kirchner J, Bruckmann NM, et al. Multiparametric 18F-FDG PET/MRI-based radiomics for prediction of pathological complete response to neoadjuvant chemotherapy in breast cancer. Cancers (Basel). 2022;14:1727.
Backhaus P, Burg MC, Asmus I, et al. Initial Results of 68Ga-FAPI-46 PET/MRI to assess response to neoadjuvant chemotherapy in breast cancer. J Nucl Med. 2023;64:717-723.
